A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a fully integrated biopharmaceutical company with two commercial products for patients impacted by kidney disease. We have built a business focused on developing and commercializing innovative therapeutics that we believe serve as a foundation for future growth, including by contributing net product revenue to support the development and advancement of our robust pipeline of mid-stage programs targeting rare kidney diseases and early-stage programs targeting kidney disease and non-kidney focused indications. We have established the Company as a leader in the kidney community and believe our cross-organizational expertise in kidney disease positions us for success. Chronic kidney disease, or CKD, is a condition in which the kidneys are progressively damaged to the point that they cannot properly filter the blood circulating in the body.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 236M | 236M | 160M | 195M | 293M | 214M |
| Net Income | -5.3M | -5.3M | -69M | -52M | -94M | -282M |
| EPS | $-0.02 | $-0.02 | $-0.33 | $-0.28 | $-0.52 | $-1.70 |
| Free Cash Flow | 68M | 68M | -41M | -23M | -73M | -253M |
| ROIC | 4.9% | 7.9% | -22.9% | -19.1% | -17.9% | -6536.0% |
| Gross Margin | 70.9% | 70.9% | 77.5% | 58.0% | 60.5% | 19.2% |
| Debt/Equity | 1.48 | 1.48 | -0.86 | -2.00 | 24.29 | 3.09 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | 23M | 23M | -50M | -46M | -81M | -265M |
| Operating Margin | 9.9% | 9.9% | -31.5% | -23.8% | -27.6% | -123.8% |
| ROE | -16.4% | -16.4% | - | - | -1801.6% | -381.1% |
| Shares Outstanding | 267M | 267M | 210M | 185M | 181M | 166M |
Akebia Therapeutics, Inc. passes 2 of 9 quality checks, indicating weak fundamentals.
On a free-cash-flow basis, the stock trades at 6.2x vs a median of 6.8x. The company's 5-year average gross margin is 57.2%. At current prices, the estimated annualized return to fair value is -19.0%.
Akebia Therapeutics, Inc. (AKBA) has a 5-year average return on invested capital (ROIC) of -13.0%. This is below average and may indicate limited pricing power.
Akebia Therapeutics, Inc. (AKBA) has a market capitalization of $417M. It is classified as a small-cap stock.
Akebia Therapeutics, Inc. (AKBA) does not currently pay a regular dividend.
Akebia Therapeutics, Inc. (AKBA) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Akebia Therapeutics, Inc. (AKBA) reported annual revenue of $236 million in its most recent fiscal year, based on SEC EDGAR filings.
Akebia Therapeutics, Inc. (AKBA) has a net profit margin of -2.3%. The company is currently unprofitable.
Akebia Therapeutics, Inc. (AKBA) generated $68 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
Akebia Therapeutics, Inc. (AKBA) has a debt-to-equity ratio of 1.48. This indicates moderate leverage.
Akebia Therapeutics, Inc. (AKBA) reported earnings per share (EPS) of $-0.02 in its most recent fiscal year.
Akebia Therapeutics, Inc. (AKBA) has a return on equity (ROE) of -16.4%. A negative ROE may indicate losses or negative equity.
Akebia Therapeutics, Inc. (AKBA) has a 5-year average gross margin of 57.2%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 13 years of financial data for Akebia Therapeutics, Inc. (AKBA), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Akebia Therapeutics, Inc. (AKBA) has a book value per share of $0.12, based on its most recent annual SEC filing.